Real-life outcomes of unselected acute promyelocytic leukemia patients: a single-center 14-year experience
References
- 1. DE BRAEKELEER E., DOUET-GUILBERT N., and DE BRAEKELEER M., RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol, 2014. 7(3): p. 347–357.
- 2. GIRI S., PATHAK R., ARYAL M.R., KARMACHARYA P., and BHATT V.R., Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. Future Oncol, 2017. 13(17): p. 1455–1457.
- 3. THULER L.C.S. and POMBO-DE-OLIVEIRA M.S., Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Ann Hematol, 2017. 96(3): p. 355–362.
- 4. DINMOHAMED A.G. and VISSER O., Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem Cell Investig, 2019. 6: p. 37–37.
- 5. KANTARJIAN H.M., KEATING M.J., WALTERS R.S., ESTEY E.H., MCCREDIE K.B., SMITH T.L., et al., Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med, 1986. 80(5): p. 789–97.
- 6. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., OGDEN A., et al., All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997. 337(15): p. 1021–8.
- 7. FENAUX P., CASTAIGNE S., DOMBRET H., ARCHIMBAUD E., DUARTE M., MOREL P., et al., All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood, 1992. 80(9): p. 2176–81.
- 8. LO-COCO F., AVVISATI G., VIGNETTI M., THIEDE C., ORLANDO S.M., IACOBELLI S., et al., Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med, 2013. 369(2): p. 111–121.
- 9. SANZ M.A., MONTESINOS P., RAYÓN C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–5146.
- 10. MICOL J.B., RAFFOUX E., BOISSEL N., LENGLINE E., CANET E., DANIEL M.T., et al., Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer, 2014. 50(6): p. 1159–68.
- 11. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MÖLLGÅRD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–1134.
- 12. PAGONI M., GAROFALAKI M., PANITSAS F., MANOLA K., PSARRA K., ECONOMOPOULOS P., et al., Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis, 2011. 3(1): p. e2011053–e2011053.
- 13. KARIM F., SHAIKH U., ADIL S.N., and KHURSHID M., Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J, 2014. 55(8): p. 443–447.
- 14. SILVA W.F.D., JR., ROSA L.I.D., MARQUEZ G.L., BASSOLLI L., TUCUNDUVA L., SILVEIRA D.R.A., et al., Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil – Early Deaths Are Still a Problem. Clin Lymphoma Myeloma Leuk, 2019. 19(2): p. e116–e122.
- 15. PAULSON K., SEREBRIN A., LAMBERT P., BERGERON J., EVERETT J., KEW A., et al., Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol, 2014. 166(5): p. 660–666.
- 16. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–1254.
- 17. MCCLELLAN J.S., KOHRT H.E., COUTRE S., GOTLIB J.R., MAJETI R., ALIZADEH A.A., et al., Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica, 2012. 97(1): p. 133.
- 18. LO-COCO F., AVVISATI G., VIGNETTI M., BRECCIA M., GALLO E., RAMBALDI A., et al., Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010. 116(17): p. 3171–9.
- 19. SANZ M.A., LO COCO F., MARTÍN G., AVVISATI G., RAYÓN C., BARBUI T., et al., Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 2000. 96(4): p. 1247–1253.
- 20. CHEN Y., KANTARJIAN H., WANG H., CORTES J., and RAVANDI F., Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer, 2012. 118(23): p. 5811–8.
- 21. SANZ M.A., MONTESINOS P., VELLENGA E., RAYON C., DE LA SERNA J., PARODY R., et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008. 112(8): p. 3130–4.
- 22. ADES L., SANZ M.A., CHEVRET S., MONTESINOS P., CHEVALLIER P., RAFFOUX E., et al., Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008. 111(3): p. 1078–84.
- 23. KELAIDI C., CHEVRET S., DE BOTTON S., RAFFOUX E., GUERCI A., THOMAS X., et al., Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol, 2009. 27(16): p. 2668–76.
- 24. SOBAS M., CZYŻ A., MONTESINOS P., ARMATYS A., HELBIG G., HOŁOWIECKA A., et al., Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clin Lymphoma Myeloma Leuk, 2019.
- 25. JÁCOMO R.H., MELO R.A.M., SOUTO F.R., DE MATTOS É.R., DE OLIVEIRA C.T., FAGUNDES E.M., et al., Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica, 2007. 92(10): p. 1431.
- 26. SANZ M.A., MONTESINOS P., RAYON C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–46.
- 27. DE LA SERNA J., MONTESINOS P., VELLENGA E., RAYON C., PARODY R., LEON A., et al., Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008. 111(7): p. 3395–402.
- 28. SANZ M.A. and MONTESINOS P., Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res, 2010. 125: p. S51–S54.
- 29. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MOLLGARD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–34.
- 30. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–54.
- 31. BURNETT A.K., HILLS R.K., GRIMWADE D., JOVANOVIC J.V., CRAIG J., MCMULLIN M.F., et al., Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia, 2013. 27(4): p. 843–851.
- 32. LENGFELDER E., GORLICH D., NOWAK D., SPIEKERMANN K., HAFERLACH C., KRUG U., et al., Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. Eur J Haematol, 2018. 100(2): p. 154–162.
- 33. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., WOODS W.G., et al., All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 2002. 100(13): p. 4298–302.
- 34. NØRGAARD J.M., FRIIS L.S., KRISTENSEN J.S., SEVERINSEN M.T., MØLLE I., MARCHER C.W., et al., Addressing the room for improvement in management of acute promyelocytic leukemia. European Journal of Haematology, 2019. 102(6): p. 479–485.
- 35. REGO E.M., KIM H.T., RUIZ-ARGUELLES G.J., UNDURRAGA M.S., URIARTE MDEL R., JACOMO R.H., et al., Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013. 121(11): p. 1935–43.
Language: English
Page range: 138 - 145
Submitted on: Feb 10, 2020
Published on: Aug 10, 2020
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2020 Omer Faruk Akcay, Haci Hasan Yeter, Yahya Buyukasik, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.